221 related articles for article (PubMed ID: 35078818)
1. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.
Li Z; Wu Y; Yates ME; Tasdemir N; Bahreini A; Chen J; Levine KM; Priedigkeit NM; Nasrazadani A; Ali S; Buluwela L; Arnesen S; Gertz J; Richer JK; Troness B; El-Ashry D; Zhang Q; Gerratana L; Zhang Y; Cristofanilli M; Montanez MA; Sundd P; Wallace CT; Watkins SC; Fumagalli C; Guerini-Rocco E; Zhu L; Tseng GC; Wagle N; Carroll JS; Jank P; Denkert C; Karsten MM; Blohmer JU; Park BH; Lucas PC; Atkinson JM; Lee AV; Oesterreich S
Cancer Res; 2022 Apr; 82(7):1321-1339. PubMed ID: 35078818
[TBL] [Abstract][Full Text] [Related]
2. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
3. FOXA1 Reprogramming Dictates Retinoid X Receptor Response in ESR1-Mutant Breast Cancer.
Wu Y; Li Z; Wedn AM; Casey AN; Brown D; Rao SV; Omarjee S; Hooda J; Carroll JS; Gertz J; Atkinson JM; Lee AV; Oesterreich S
Mol Cancer Res; 2023 Jun; 21(6):591-604. PubMed ID: 36930833
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S
Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
6. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
Chandarlapaty S; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Voi M; Gnant M; Hortobagyi G; Baselga J; Moynahan ME
JAMA Oncol; 2016 Oct; 2(10):1310-1315. PubMed ID: 27532364
[TBL] [Abstract][Full Text] [Related]
9. Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients.
Franken A; Honisch E; Reinhardt F; Meier-Stiegen F; Yang L; Jaschinski S; Esposito I; Alberter B; Polzer B; Huebner H; Fasching PA; Pancholi S; Martin LA; Ruckhaeberle E; Schochter F; Tzschaschel M; Hartkopf AD; Mueller V; Niederacher D; Fehm T; Neubauer H
J Mol Diagn; 2020 Jan; 22(1):111-121. PubMed ID: 31669227
[TBL] [Abstract][Full Text] [Related]
10. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.
Wang P; Bahreini A; Gyanchandani R; Lucas PC; Hartmaier RJ; Watters RJ; Jonnalagadda AR; Trejo Bittar HE; Berg A; Hamilton RL; Kurland BF; Weiss KR; Mathew A; Leone JP; Davidson NE; Nikiforova MN; Brufsky AM; Ambros TF; Stern AM; Puhalla SL; Lee AV; Oesterreich S
Clin Cancer Res; 2016 Mar; 22(5):1130-7. PubMed ID: 26500237
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.
Sundaresan TK; Dubash TD; Zheng Z; Bardia A; Wittner BS; Aceto N; Silva EJ; Fox DB; Liebers M; Kapur R; Iafrate J; Toner M; Maheswaran S; Haber DA
Breast Cancer Res Treat; 2021 Jul; 188(1):43-52. PubMed ID: 34101078
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
Ross DS; Zehir A; Brogi E; Konno F; Krystel-Whittemore M; Edelweiss M; Berger MF; Toy W; Chandarlapaty S; Razavi P; Baselga J; Wen HY
Mod Pathol; 2019 Jan; 32(1):81-87. PubMed ID: 30158597
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Sueta A; Tomiguchi M; Murakami K; Omoto Y; Iwase H
BMC Cancer; 2017 Nov; 17(1):786. PubMed ID: 29166868
[TBL] [Abstract][Full Text] [Related]
15. Detection of Activating Estrogen Receptor Gene (
Paolillo C; Mu Z; Rossi G; Schiewer MJ; Nguyen T; Austin L; Capoluongo E; Knudsen K; Cristofanilli M; Fortina P
Clin Cancer Res; 2017 Oct; 23(20):6086-6093. PubMed ID: 28679775
[No Abstract] [Full Text] [Related]
16. Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
Yanagawa T; Kagara N; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Jun; 163(2):231-240. PubMed ID: 28283903
[TBL] [Abstract][Full Text] [Related]
17. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.
Li Z; McGinn O; Wu Y; Bahreini A; Priedigkeit NM; Ding K; Onkar S; Lampenfeld C; Sartorius CA; Miller L; Rosenzweig M; Cohen O; Wagle N; Richer JK; Muller WJ; Buluwela L; Ali S; Bruno TC; Vignali DAA; Fang Y; Zhu L; Tseng GC; Gertz J; Atkinson JM; Lee AV; Oesterreich S
Nat Commun; 2022 Apr; 13(1):2011. PubMed ID: 35440136
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients.
Babayan A; Hannemann J; Spötter J; Müller V; Pantel K; Joosse SA
PLoS One; 2013; 8(9):e75038. PubMed ID: 24058649
[TBL] [Abstract][Full Text] [Related]
19. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines.
Gelsomino L; Panza S; Giordano C; Barone I; Gu G; Spina E; Catalano S; Fuqua S; Andò S
Cancer Lett; 2018 Aug; 428():12-20. PubMed ID: 29702197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]